Journal of Critical Care
Volume 25, Issue 2 , Pages 287-293, June 2010

The 4Ts scoring system for heparin-induced thrombocytopenia in medical-surgical intensive care unit patients☆

  • Mark Andrew Crowther, MD, MSc

      Affiliations

    • Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario Canada
    • Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario Canada
    • Corresponding Author InformationCorresponding author. St. Joseph's Hospital, Hamilton, Ontario, Canada L8N 4A6. Tel.: +1 905 521 6024; fax: + 1 905 540 6568.
    • ,
  • Deborah J. Cook, MD, MSc

      Affiliations

    • Department of Medicine, McMaster University, Hamilton, Ontario Canada
    • ,
  • Martin Albert, MD

      Affiliations

    • Pharmacy Department (DW) and Department of Medicine (MA,YS,SL), Université de Montréal, Montréal, Quebec, Canada
    • ,
  • David Williamson, MD

      Affiliations

    • Pharmacy Department (DW) and Department of Medicine (MA,YS,SL), Université de Montréal, Montréal, Quebec, Canada
    • ,
  • Maureen Meade, MD, MSc

      Affiliations

    • Department of Medicine, McMaster University, Hamilton, Ontario Canada
    • Department of Clinical Epidemiology and Biostatisitics, McMaster University, Hamilton, Ontario Canada
    • ,
  • John Granton, MD

      Affiliations

    • Department of Medicine, University of Toronto, Toronto, Canada
    • ,
  • Yoanna Skrobik, MD

      Affiliations

    • Pharmacy Department (DW) and Department of Medicine (MA,YS,SL), Université de Montréal, Montréal, Quebec, Canada
    • ,
  • Stephan Langevin, MD

      Affiliations

    • Department of Medicine, Laval University, Quebec, Canada
    • ,
  • Sangeeta Mehta, MD

      Affiliations

    • Department of Medicine, University of Toronto, Toronto, Canada
    • ,
  • Paul Hebert, MD

      Affiliations

    • Department of Medicine, University of Ottawa, Ottawa, Ontario Canada
    • ,
  • Gordon H. Guyatt, MD

      Affiliations

    • Department of Medicine, McMaster University, Hamilton, Ontario Canada
    • Department of Clinical Epidemiology and Biostatisitics, McMaster University, Hamilton, Ontario Canada
    • ,
  • William Geerts, MD

      Affiliations

    • Department of Medicine, University of Toronto, Toronto, Canada
    • ,
  • Christian Rabbat, MD

      Affiliations

    • Department of Medicine, McMaster University, Hamilton, Ontario Canada
    • ,
  • James Douketis, MD

      Affiliations

    • Department of Medicine, McMaster University, Hamilton, Ontario Canada
    • ,
  • Nicole Zytaruk, RN

      Affiliations

    • Department of Medicine, McMaster University, Hamilton, Ontario Canada
    • ,
  • Joanne Sheppard

      Affiliations

    • Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario Canada
    • ,
  • Andreas Greinacher, MD

      Affiliations

    • Department of Immunology and Transfusion Medicine, Ernst-Moritz-Arndt-University-Greifswald, Greifswald, Germany
    • ,
  • Theodore E. Warkentin, MD

      Affiliations

    • Department of Medicine, McMaster University, Hamilton, Ontario Canada
    • Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario Canada
    • ,
  • For the Canadian Critical Care Trials Group

published online 11 February 2010.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

☆ Conflict of interest statement: Andreas Greinacher is a consultant for Schering-Plough (Whitehouse Station, NJ, USA) (drug Orgaran); Mitsubishi Pharma (Osaka, Japan) (drug Argatroban); and has received speakers honoraria from Schering-Plough, Mitsubishi Pharma, GlaxoSmithKline (Brentford, Middlesex, USA). Dr Rabbat has acted as a consultant to Pfizer Inc. Dr Crowther has received speaker fees from Bayer (Pittsburgh, PA, USA), Boehringer Ingelheim (Ingelheim am Rhein, Germany), Sanofi-Aventis (Bridgewater, NJ, USA), Pfizer (New York, NY), Leo Laboratories (Copenhagen, Denmark), and Organon (Wyeth); has received unrestricted research funds from Leo Laboratories; and has acted as a consultant for Bayer, Boehringer Ingelheim, Sanofi Aventis, Pfizer, Leo Laboratories, and Organon (Schering-Plough). Dr Warkentin has acted as a consultant for Genetic Testing Institute (GTI) Inc (Waukesha, WI, USA); GlaxoSmithKline; Organon Inc (part of Schering-Plough); and Pfizer Canada. He has received speaking fees from GlaxoSmithKline and Sanofi-Aventis. He has provided paid expert testimony on topic of heparin-induced thrombocytopenia and has received research funding from GTI Inc, GlaxoSmithKline, and Organon Inc (part of Schering-Plough).

PII: S0883-9441(10)00006-7

doi:10.1016/j.jcrc.2009.12.006

Journal of Critical Care
Volume 25, Issue 2 , Pages 287-293, June 2010

Article Tools

* Image Usage & Resolution